Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected by thyroid cancer. A 58-year-old man diagnosed with Hurthle cell thyroid cancer, who was undergoing treatment with lenvatinib, developed maxillary osteonecrosis after a dental extraction. No other concomitant local or systemic risk factors for MRONJ were present. With new cancer therapies applied every year, it is important to note this novel case of lenvatinib osteonecrosis of the jaw in a patient undergoing cancer treatment.

Mauceri, R., Panzarella, V., Morreale, I., Campisi, G. (2019). Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 48(12), 1530-1532 [10.1016/j.ijom.2019.07.010].

Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib

Mauceri, R;Panzarella, V;Morreale, I;Campisi, G
2019-01-01

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected by thyroid cancer. A 58-year-old man diagnosed with Hurthle cell thyroid cancer, who was undergoing treatment with lenvatinib, developed maxillary osteonecrosis after a dental extraction. No other concomitant local or systemic risk factors for MRONJ were present. With new cancer therapies applied every year, it is important to note this novel case of lenvatinib osteonecrosis of the jaw in a patient undergoing cancer treatment.
Settore MED/28 - Malattie Odontostomatologiche
Mauceri, R., Panzarella, V., Morreale, I., Campisi, G. (2019). Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 48(12), 1530-1532 [10.1016/j.ijom.2019.07.010].
File in questo prodotto:
File Dimensione Formato  
Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Versione Editoriale
Dimensione 400.85 kB
Formato Adobe PDF
400.85 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/381380
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 13
social impact